These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11191729)

  • 1. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity.
    Carlson MK; Gleason PP; Sen S
    Pharmacotherapy; 2001 Jan; 21(1):108-13. PubMed ID: 11191729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
    Merli G; Spiro TE; Olsson CG; Abildgaard U; Davidson BL; Eldor A; Elias D; Grigg A; Musset D; Rodgers GM; Trowbridge AA; Yusen RD; Zawilska K;
    Ann Intern Med; 2001 Feb; 134(3):191-202. PubMed ID: 11177331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.
    Hillbom M; Erilä T; Sotaniemi K; Tatlisumak T; Sarna S; Kaste M
    Acta Neurol Scand; 2002 Aug; 106(2):84-92. PubMed ID: 12100367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
    Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
    J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
    Colwell CW; Spiro TE; Trowbridge AA; Morris BA; Kwaan HC; Blaha JD; Comerota AJ; Skoutakis VA
    J Bone Joint Surg Am; 1994 Jan; 76(1):3-14. PubMed ID: 8288662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep venous thrombosis and pulmonary embolism. Part 1. Initial treatment: usually a low-molecular-weight heparin.
    Prescrire Int; 2013 Apr; 22(137):99-101, 103-4. PubMed ID: 23662321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients.
    Cestac P; Bagheri H; Lapeyre-Mestre M; Sié P; Fouladi A; Maupas E; Léger P; Fontan B; Massip P; Montastruc JL
    Drug Saf; 2003; 26(3):197-207. PubMed ID: 12580648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical bleeding after pre-operative unfractionated heparin and low molecular weight heparin for coronary bypass surgery.
    Renda G; Di Pillo R; D'Alleva A; Sciartilli A; Zimarino M; De Candia E; Landolfi R; Di Giammarco G; Calafiore A; De Caterina R
    Haematologica; 2007 Mar; 92(3):366-73. PubMed ID: 17339186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous factor Xa and IIa formation and on thrombelastometry profiles.
    Cvirn G; Wagner T; Juergens G; Koestenberger M
    Blood Coagul Fibrinolysis; 2009 Jan; 20(1):71-7. PubMed ID: 20339323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.
    Sherman DG; Albers GW; Bladin C; Fieschi C; Gabbai AA; Kase CS; O'Riordan W; Pineo GF;
    Lancet; 2007 Apr; 369(9570):1347-1355. PubMed ID: 17448820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF; Neuhart E
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
    De A; Roy P; Garg VK; Pandey NK
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):57-61. PubMed ID: 19844176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
    Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
    Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; Dunwiddie CT; Perrone MH
    Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):908-14. PubMed ID: 9633930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
    N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.